In this issue:
A new oral IL-23-receptor antagonist for plaque psoriasis
A new PDE4 inhibitor for atopic dermatitis and plaque psoriasis
Bimekizumab for severe palmoplantar pustular psoriasis
Safety of biologic therapy + methotrexate
Apremilast for moderate-to-severe genital psoriasis
Orismilast in moderate-to-severe psoriasis
Multi-failure psoriasis patients
Guselkumab complete skin clearance for 5 years
Drug survival of biologic therapies for palmoplantar pustulosis
Efficacy and safety of newer topical therapies in psoriasis
Please login below to download this issue (PDF)